Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.
PRO-CTCAE
PROM
lung cancer
patient-reported outcomes
side effects
symptomatic adverse events
Journal
JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
17
12
2020
accepted:
07
07
2021
revised:
13
06
2021
entrez:
14
9
2021
pubmed:
15
9
2021
medline:
15
9
2021
Statut:
epublish
Résumé
The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to specific patient populations to enable the implementation of PRO-CTCAE-based symptom monitoring in clinical practice. The aim of this study is to develop a PRO-CTCAE-based subset relevant to patients with lung cancer that can be used for monitoring during multidisciplinary clinical practice. The PRO-CTCAE-based subset for patients with lung cancer was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made. A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general). On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE-based lung cancer subset internationally and in real-world clinical practice settings.
Sections du résumé
BACKGROUND
BACKGROUND
The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to specific patient populations to enable the implementation of PRO-CTCAE-based symptom monitoring in clinical practice.
OBJECTIVE
OBJECTIVE
The aim of this study is to develop a PRO-CTCAE-based subset relevant to patients with lung cancer that can be used for monitoring during multidisciplinary clinical practice.
METHODS
METHODS
The PRO-CTCAE-based subset for patients with lung cancer was generated using a mixed methods approach based on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made.
RESULTS
RESULTS
A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22) participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of breath, fatigue, constipation, nausea, sadness, and pain (general).
CONCLUSIONS
CONCLUSIONS
On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness of this PRO-CTCAE-based lung cancer subset internationally and in real-world clinical practice settings.
Identifiants
pubmed: 34519658
pii: v7i3e26574
doi: 10.2196/26574
pmc: PMC8479599
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e26574Informations de copyright
©Evalien Veldhuijzen, Iris Walraven, José Belderbos. Originally published in JMIR Cancer (https://cancer.jmir.org), 14.09.2021.
Références
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32
pubmed: 19920223
J Patient Rep Outcomes. 2019 Mar 21;3(1):19
pubmed: 30900035
J Patient Rep Outcomes. 2019 Aug 22;3(1):56
pubmed: 31440865
Lung Cancer. 1995 Jun;12(3):199-220
pubmed: 7655830
Eur J Cancer. 2014 Jul;50(11):1925-41
pubmed: 24825114
Psychooncology. 2003 Oct-Nov;12(7):694-708
pubmed: 14502594
Qual Life Res. 2015 Jul;24(7):1707-18
pubmed: 25589231
J Patient Rep Outcomes. 2020 Oct 6;4(1):81
pubmed: 33025309
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Value Health. 2009 Nov-Dec;12(8):1075-83
pubmed: 19804437
J Clin Oncol. 2012 Dec 1;30(34):4249-55
pubmed: 23071244
Cancer. 2000 Oct 1;89(7):1634-46
pubmed: 11013380
Ann Oncol. 2015 Sep;26(9):1846-1858
pubmed: 25888610
Ann Oncol. 2017 Nov 1;28(11):2874-2881
pubmed: 28945875
Clin Trials. 2016 Jun;13(3):331-7
pubmed: 26542025
Acta Oncol. 2019 May;58(5):596-602
pubmed: 30702003
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28423407
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Am Soc Clin Oncol Educ Book. 2019 Jan;39:332-340
pubmed: 31099640
Qual Life Res. 2009 Feb;18(1):115-23
pubmed: 19105048
Support Care Cancer. 2014 Jan;22(1):79-85
pubmed: 23995815
Support Care Cancer. 2013 Jun;21(6):1525-50
pubmed: 23314601
Eur Respir J. 2016 Sep;48(3):852-60
pubmed: 27390281
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
J Clin Oncol. 2004 Sep 1;22(17):3485-90
pubmed: 15337796
J Natl Cancer Inst. 2014 Jul 08;106(7):
pubmed: 25006191
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52
pubmed: 30102201
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Clin Cancer Res. 2016 Apr 1;22(7):1553-8
pubmed: 26758559
Cancer Nurs. 2013 Nov-Dec;36(6):E1-E16
pubmed: 23047799
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
J Clin Oncol. 2014 May 10;32(14):1480-501
pubmed: 24711559